Please use this identifier to cite or link to this item:
Title: Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.
Authors: Almeida, Antonio M
Prebet, Thomas
Itzykson, Raphael
Ramos, Fernando
Al-Ali, Haifa
Shammo, Jamile
Pinto, Ricardo
Maurillo, Luca
Wetzel, Jaime
Musto, Pellegrino
Van De Loosdrecht, Arjan A
Costa, Maria Joao
Esteves, Susana
Burgstaller, Sonja
Stauder, Reinhard
Autzinger, Eva M
Lang, Alois
Krippl, Peter
Geissler, Dietmar
Falantes, Jose Francisco
Pedro, Carmen
Bargay, Joan
Deben, Guillermo
Garrido, Ana
Bonanad, Santiago
Diez-Campelo, Maria
Thepot, Sylvain
Ades, Lionel
Sperr, Wolfgang R
Valent, Peter
Fenaux, Pierre
Sekeres, Mikkael A
Greil, Richard
Pleyer, Lisa
Keywords: acute erythroleukemia;azacitidine;decitabine
metadata.dc.subject.mesh: Adult
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Bone Marrow
Cytogenetic Analysis
Leukemia, Erythroblastic, Acute
Middle Aged
Proportional Hazards Models
Retrospective Studies
Survival Analysis
Treatment Outcome
Issue Date: 14-Apr-2017
Abstract: Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p ≤ 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.
metadata.dc.identifier.doi: 10.3390/ijms18040837
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5412421.pdf1,53 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons